Publications by authors named "A el Beshlawy"
Inhibitor development is the most severe complication of hemophilia A (HA) care and is associated with increased morbidity and mortality. This study aimed to use a novel immunoglobulin G epitope mapping method to explore the factor VIII (FVIII)-specific epitope profile in the SIPPET cohort population and to develop an epitope mapping-based inhibitor prediction model. The population consisted of 122 previously untreated patients with severe HA who were followed up for 50 days of exposure to FVIII or 3 years, whichever occurred first.
View Article and Find Full Text PDFβ-Thalassemia is one of the most common monogenetic diseases worldwide, with a particularly high prevalence in the Middle East region. As such, we have developed long-standing experience with disease management and devising solutions to address challenges attributed to resource limitations. The region has also participated in the majority of clinical trials and development programs of iron chelators and more novel ineffective erythropoiesis-targeted therapy.
View Article and Find Full Text PDFArticle Synopsis
- Kids with sickle cell disease often need help to get rid of extra iron from blood transfusions, and there are two treatments called deferiprone and deferoxamine that help with this.
- A study looked at 142 kids under 18 years old who were being treated with either deferiprone or deferoxamine, showing that both treatments worked similarly in reducing iron levels after 12 months.
- Deferiprone is a pill that might be easier for kids to take, and it wasn't found to have any new safety problems compared to deferoxamine.
A prognostic scoring system that can differentiate β-thalassemia patients based on mortality risk is lacking. We analysed data from 3145 β-thalassemia patients followed through a retrospective cohort design for the outcome of death. An a priori list of prognostic variables was collected.
View Article and Find Full Text PDF